865200-20-0 Usage
Description
GIRIPLADIB is a pharmaceutical compound that functions as an inhibitor of cytosolic phospholipase A2 (cPLA2). It is designed to enhance the sensitivity of tumors to radiation therapy, particularly in the context of lung cancer treatment.
Uses
Used in Oncology:
GIRIPLADIB is used as a radiosensitizing agent for enhancing the effectiveness of radiation therapy in lung cancer treatment. By inhibiting cPLA2, it increases the sensitivity of tumor cells to radiation, leading to improved therapeutic outcomes in animal models of lung cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 865200-20-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,2,0 and 0 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 865200-20:
(8*8)+(7*6)+(6*5)+(5*2)+(4*0)+(3*0)+(2*2)+(1*0)=150
150 % 10 = 0
So 865200-20-0 is a valid CAS Registry Number.
InChI:InChI=1/C41H36ClF3N2O4S/c42-33-22-23-37-35(26-33)34(16-9-10-28-18-20-31(21-19-28)40(48)49)38(47(37)39(29-11-3-1-4-12-29)30-13-5-2-6-14-30)24-25-46-52(50,51)27-32-15-7-8-17-36(32)41(43,44)45/h1-8,11-15,17-23,26,39,46H,9-10,16,24-25,27H2,(H,48,49)
865200-20-0Relevant articles and documents
Process for the synthesis of sulfonyl halides and sulfonamides from sulfonic acid salts
-
Page/Page column 8, (2008/06/13)
The present invention provides synthetic processes for the preparation of sulfonyl halides of Formula Ar—(R)z—O2—X and sulfonamides of Formula Ar—(R)2—SO2—NR4R5, where the constituent varia
